NANG KUANG Business Summary

Nang Kuang Pharmaceutical Co., Ltd. (1752.TW) is a premier Taiwanese pharmaceutical manufacturer specializing in high-barrier injectables and sterile production technologies. The company operates a B2B revenue model, supplying healthcare institutions and international partners with a portfolio segmented into Small Volume Parenterals (SVP, ~35% of revenue), Large Volume Parenterals (LVP, ~26%), and oral solids including tablets and capsules (~24%). As of early 2026, Nang Kuang maintains a dominant position in the domestic IV fluid market, with approximately 78% of its revenue generated in Taiwan, while strategically expanding its export footprint and CDMO services in China, Japan, and the United States. The company competes directly with Lotus Pharmaceutical, Bora Pharmaceuticals, YungShin Global Holding, and TTY Biopharm; it distinguishes itself through its advanced aseptic production lines for pre-filled syringes and non-PVC infusion bags, positioning the firm as a critical supplier for the high-growth acute care and oncology segments. The company was established in 1963 by Chen Wang-chuan and continues to operate as a family-led enterprise under the leadership of Chairman Chen Li-pi and President Wang Yu-chih. Wang Yu-chih, widely recognized as a foundational figure in Taiwan’s pharmaceutical sector, directs the firm’s strategic R&D and international regulatory alignment, having successfully spearheaded the company's expansion into the U.S. and Japanese generic markets. The leadership team is supported by a board of directors comprising founding family members and independent directors with deep expertise in chemical engineering and clinical medicine. Significant ownership is held through family-controlled entities like Zhengzhao Investment and Song-ban Investment, complemented by institutional backing from major domestic funds such as Cathay Life Insurance, ensuring a stable governance structure focused on long-term capital-intensive manufacturing upgrades.